Bain Capital Life Sciences Investors’s X4 Pharmaceuticals XFOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.07M | Hold |
563,859
| – | – | 0.13% | 22 |
|
|
2025
Q1 | $4M | Hold |
563,859
| – | – | 0.59% | 15 |
|
|
2024
Q4 | $12.4M | Hold |
563,859
| – | – | 1.46% | 13 |
|
|
2024
Q3 | $11.3M | Hold |
563,859
| – | – | 1.18% | 13 |
|
|
2024
Q2 | $9.81M | Hold |
563,859
| – | – | 1.08% | 15 |
|
|
2024
Q1 | $23.5M | Hold |
563,859
| – | – | 1.89% | 13 |
|
|
2023
Q4 | $14.2M | Buy |
563,859
+31,839
| +6% | +$801K | 1.36% | 17 |
|
|
2023
Q3 | $17.4M | Hold |
532,020
| – | – | 1.95% | 13 |
|
|
2023
Q2 | $31M | Buy |
532,020
+125,270
| +31% | +$7.29M | 3.19% | 11 |
|
|
2023
Q1 | $10.6M | Hold |
406,750
| – | – | 1.33% | 22 |
|
|
2022
Q4 | $12.1M | Buy |
406,750
+193,769
| +91% | +$5.77M | 1.35% | 20 |
|
|
2022
Q3 | $10.9M | Buy |
212,981
+112,330
| +112% | +$5.76M | 1.3% | 20 |
|
|
2022
Q2 | $2.91M | Hold |
100,651
| – | – | 0.34% | 34 |
|
|
2022
Q1 | $5.28M | Buy |
100,651
+4,433
| +5% | +$233K | 0.51% | 28 |
|
|
2021
Q4 | $6.61M | Buy |
96,218
+25,567
| +36% | +$1.76M | 0.52% | 26 |
|
|
2021
Q3 | $11.2M | Hold |
70,651
| – | – | 0.7% | 23 |
|
|
2021
Q2 | $13.8M | Hold |
70,651
| – | – | 0.9% | 21 |
|
|
2021
Q1 | $18.2M | Buy |
70,651
+15,701
| +29% | +$4.06M | 1.03% | 19 |
|
|
2020
Q4 | $10.6M | Hold |
54,950
| – | – | 0.67% | 20 |
|
|
2020
Q3 | $11.2M | Hold |
54,950
| – | – | 1.04% | 18 |
|
|
2020
Q2 | $15.4M | Hold |
54,950
| – | – | 1.61% | 13 |
|
|
2020
Q1 | $16.5M | Hold |
54,950
| – | – | 2.79% | 8 |
|
|
2019
Q4 | $17.6M | Buy |
+54,950
| New | +$17.6M | 2.63% | 7 |
|